

The U.S. Census Bureau website contains AI/AN specific data at the Tribal census tract level. Data is provided at <http://factfinder.census.gov/home/aian/index.html> by Tribe and language; reservations and other AI/AN areas; country and Tribal census tract level; and economic category.

The Public Health Service (PHS) strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of the facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American People.

Dated: March 21, 2006.

Robert G. McSwain,

Deputy Director, Indian Health Service.

[FR Doc. 06-3008 Filed 3-29-06; 8:45 am]

BILLING CODE 4165-16-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Establishment

Pursuant to the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), the Director, National Institutes of Health (NIH), announces the establishment of the National Cancer Institute Clinical Trials Advisory Committee (Committee).

This Committee shall advise the Director, NCI, NCI Deputy Directors, and the Director of each NCI Division on the NCI-support national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trials process.

The Committee will consist of 25 members, including the Chair, appointed by the Director, NCI. Members shall be authorities knowledgeable in the fields of community, surgical, medical, and radiation oncology, patient advocacy, extramural clinical investigation, regulatory agencies, pharmaceutical industry, public health, clinical trials design, management and evaluation, drug development and developmental therapeutics, cancer prevention and

control research in the fields of interest to NCI.

Duration of this committee is continuing unless formally determined by the Director, NCI that termination would be in the best public interest.

Dated: March 21, 2006.

Elias A. Zerhouni,

Director, National Institutes of Health.

[FR Doc. 06-3096 Filed 3-29-06; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Immunogenic Peptides and Methods of Use for Treating and Preventing Cancer

Jay A. Berzofsky *et al.* (NCI)
U.S. Provisional Application No. 60/773,319 filed 03 Nov 2005 (HHS Reference No. E-312-2005/0-US-01)
Licensing Contact: John Stansberry; 301/435-5236; stansbej@mail.nih.gov.

Rhabdomyosarcoma is a malignant (cancerous), soft tissue tumor found in children. The most common sites are the structures of the head and neck, the urogenital tract, and the arms or legs. The inventors have discovered an epitope that is created by a chromosomal translocation that occurs in about 80% of alveolar rhabdomyosarcoma and can elicit a human cytotoxic T lymphocytes (CTL)

response in individuals who express HLA-B*7.

Many tumors express mutated tumor associated antigens that often contain T-lymphocyte epitopes. However, the immune system often remains incapable of overtaking the growth potential of the malignant cells. Previous attempts to obtain protective and therapeutic anti-tumor immunity have been moderately successful (Dagher *et al.*, *Med Pediatr Oncol* 38: 158-164 (2002) and Rodeberg *et al.*, *Cancer Immuno Immunother* 54: 526-534 (2005)). This present invention seeks to improve on previous attempts by providing more immunogenic peptides that bind to a Major Histocompatibility Complex (MHC) Class I molecule with higher affinity, and fusion proteins comprising at least one of the inventive immunogenic peptides. This discovery involves human T-cell responses to human tumors.

The National Cancer Institute welcomes statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize NCI's technology related to methods of protective and therapeutic immunogenic peptides. Please contact Dr. Patrick Twomey at 301-496-0477 or twomeyp@mail.nih.gov for more information.

Impaired Neuregulin1-Stimulated B Lymphoblast Migration as Diagnostic for Schizophrenia

Daniel Weinberger *et al.* (NIMH)
U.S. Provisional Application No. 60/735,353 filed 10 Nov 2005 (HHS Reference No. E-181-2005/1-US-01)
Licensing Contact: Norbert Pontzer; 301/435-5502; pontzern@mail.nih.gov.

Schizophrenia may be a neurodevelopmental disorder (Weinberger D.R. and Marenco S. in *Schizophrenia as a neurodevelopmental disorder*, Hirsch S., Weinberger D.R. (eds) *Schizophrenia*, 2nd ed., Blackwell Science: Oxford, UK, 2003 pp 326-348). Neuregulin1 (NRG1) plays a critical role in neuronal migration and maturation by interacting with ErbB tyrosine kinase receptors and linkage studies and genetically engineered animals have implicated NRG1-mediated signaling in the neuropathogenesis of schizophrenia. Although no technique is available to assess NRG1/ErbB mediated neural migration in living human brain, there is increasing recognition that neuronal cells and immune cells share many cellular and molecular mechanisms for cell migration and motility. These inventors showed NRG1 mediated chemotactic responses of B lymphocytes from schizophrenic patients are